Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice

Abstract

SummaryBackgroundActivated microglia‐mediated inflammation plays a key role in the pathogenesis of Alzheimer’s disease (AD). In addition, chronic activation of NLRP3 inflammasomes triggered by amyloid β peptide (Aβ) in microglia contributes to persistent neuroinflammation. Here, the primary goal was to assess whether Dihydromyricetin (DHM), a plant flavonoid compound, is effective therapies for AD; it is crucial to know whether DHM will affect microglial activation and neuroinflammation in APP/PS1 transgenic mice.MethodsAfter DHM was intraperitoneally injected in APP/PS1 double‐transgenic mice, we assessed the effect of DHM on microglial activation, the expression of NLRP3 inflammasome components, and the production of inflammatory cytokine IL‐1β by immunofluorescence and Western blot. To determine whether DHM play roles in the Aβ production and deposition, amyloid β protein precursor (APP) and β‐site APP cleaving enzyme1 (BACE1), as well as neprilysin (NEP), were detected by Western blot. Finally, behavior was tested by Morris Water Maze to illustrate whether DHM treatment has a significantly positive effect on ameliorating the memory and cognition deficits in AD.ResultsDihydromyricetin treatment significantly ameliorated memory and cognition deficits and decreased the number of activated microglia in the hippocampus and cortex of APP/PS1 mice. In addition, APP/PS1 mice show reduced activation of NLRP3 inflammasomes and reduced expression of NLRP3 inflammasome components. Furthermore, DHM could promote clearance of Aβ, a trigger for NLRP3 inflammasome activation, by increasing levels of NEP and shift microglial conversion to the M2‐specific agrinase‐1‐positive cell phenotype, which enhances microglial clearance of Aβ and its aggregates but not production of Aβ.ConclusionTaken together, our findings suggest that DHM prevents progression of AD‐like pathology through inhibition of NLRP3 inflammasome‐based microglia‐mediated neuroinflammation and may be a promising therapeutic drug for treating AD.

COX-1/EP1R Inhibition Ameliorate Deficits in Adult Neurogenesis and Social Interaction via Alleviating NLRP3/ IL-1β Activation During Hypobaric Hypoxia

“…NLRP3 and NFkB signalling pathways were shown to activate upon HH exposure [22] supports our observation where we showed their up regulation in DG. Reduction in BDNF dependent neurogenesis was simultaneous with induction in NLRP3 dependent in ammation similarly shown earlier [72]. Dramatic increase in levels of pro-in ammatory cytokines followed by microglial activation made it imperative to target in ammatory pathways in an attempt to rescue brain neurogenic capability.…”

Naringenin promotes microglial M2 polarization and Aβ degradation enzyme expression

“…Among microglia, M2 microglia reportedly express NEP and IDE and reduce Aβ plaques (Shimizu et al, ). Recently, there are a few known agents such as PF‐3845, sarsasapogenin‐AA13, and dihydromyricetin, which promoted M2 microglial and inhibited M1 microglial polarization, leading to the memory recovery in traumatic brain injury and AD models (Feng et al, ; C. Huang et al, ; Tchantchou et al, ). Furthermore, dihydromyricetin promoted the clearance of Aβ and expression of NEP in APP/PS1 transgenic mice brain (Tchantchou et al, ).…”

Molecular Level Insight Into the Benefit of Myricetin and Dihydromyricetin Uptake in Patients With Alzheimer’s Diseases

“…This causes an overall decrease in the levels of APP that can be used to produce Aβ, thereby indirectly reducing Aβ production. Furthermore, studies also showed that DMY can increase the expression of neprilysin (NEP) (Feng et al, 2018). NEP is a M13 zinc metalloproteinase family protein that can cleave Aβ peptide bonds to decompose Aβ (Kanemitsu et al, 2003;Hersh and Rodgers, 2008).…”